{"id":"thymosin-alpha","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thymosin Alpha is a naturally occurring peptide derived from thymic tissue that acts as an immunomodulator. It stimulates the differentiation and maturation of T-lymphocytes in the thymus and enhances overall immune cell function, including activation of macrophages and natural killer cells. This mechanism makes it useful in conditions characterized by immune deficiency or impaired immune response.","oneSentence":"Thymosin Alpha is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activation of immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:33.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immunodeficiency disorders"},{"name":"Chronic hepatitis B"},{"name":"Cancer immunotherapy adjunct"}]},"trialDetails":[{"nctId":"NCT07277439","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-16","conditions":"Gastric Cancer","enrollment":48},{"nctId":"NCT07103395","phase":"PHASE2","title":"A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Lung Cancer (NSCLC)","enrollment":56},{"nctId":"NCT06966687","phase":"NA","title":"Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)","status":"ENROLLING_BY_INVITATION","sponsor":"Nanjing Medical University","startDate":"2025-04-01","conditions":"Aortic Dissection, Aortic Dissection Aneurysm","enrollment":200},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT04428008","phase":"PHASE2","title":"Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients","status":"COMPLETED","sponsor":"William B. Ershler, MD","startDate":"2021-01-12","conditions":"COVID-19","enrollment":262},{"nctId":"NCT07103408","phase":"PHASE2","title":"A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-10-01","conditions":"Small-Cell Lung Cancer (SCLC)","enrollment":56},{"nctId":"NCT06821100","phase":"PHASE1","title":"Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-02","conditions":"Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination","enrollment":75},{"nctId":"NCT06829355","phase":"PHASE2","title":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-02-11","conditions":"MCRC","enrollment":52},{"nctId":"NCT05339529","phase":"NA","title":"Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)","status":"RECRUITING","sponsor":"Nanjing Medical University","startDate":"2022-07-01","conditions":"Acute Aortic Syndrome, Aortic Dissection Type a","enrollment":330},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT06598839","phase":"NA","title":"Immuno-effect of Tα1 for Stage I NSCLC","status":"RECRUITING","sponsor":"Yousheng Mao","startDate":"2024-06-30","conditions":"Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06178146","phase":"PHASE4","title":"Thymosin Alpha-1 for irAE Secondary to ICIs","status":"UNKNOWN","sponsor":"Jun Wang","startDate":"2023-09-01","conditions":"IrAE","enrollment":40},{"nctId":"NCT06024356","phase":"","title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2023-09-20","conditions":"Colorectal Neoplasms","enrollment":26},{"nctId":"NCT02867267","phase":"PHASE3","title":"The Efficacy and Safety of Ta1 for Sepsis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-09-06","conditions":"Sepsis","enrollment":1106},{"nctId":"NCT04487444","phase":"PHASE2","title":"Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection","status":"TERMINATED","sponsor":"Rhode Island Hospital","startDate":"2020-09-10","conditions":"Covid19","enrollment":56},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT05487469","phase":"NA","title":"Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2022-07-01","conditions":"Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy","enrollment":200},{"nctId":"NCT03659578","phase":"PHASE2","title":"Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-08-09","conditions":"Non-small Cell Lung Cancer","enrollment":69},{"nctId":"NCT05086614","phase":"PHASE3","title":"Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-04-01","conditions":"Stage II Colorectal Cancer, Stage III Colorectal Cancer","enrollment":2500},{"nctId":"NCT04901104","phase":"","title":"Long-term Prognosis of Patients With Sepsis After Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-07-01","conditions":"Long-term Effects of Thymosin Alpha 1 Treatment","enrollment":900},{"nctId":"NCT02473406","phase":"PHASE4","title":"Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis","status":"COMPLETED","sponsor":"Weiqin Li","startDate":"2018-03-27","conditions":"Pancreatitis, Acute Necrotizing","enrollment":508},{"nctId":"NCT04524169","phase":"PHASE4","title":"Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-11-01","conditions":"Osteoporotic Pain","enrollment":100},{"nctId":"NCT04320238","phase":"PHASE3","title":"Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-01-21","conditions":"2019 Novel Coronavirus Infection","enrollment":2944},{"nctId":"NCT02883595","phase":"PHASE4","title":"Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-03-31","conditions":"Sepsis","enrollment":20},{"nctId":"NCT03448744","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients","status":"UNKNOWN","sponsor":"Wen-hong Zhang","startDate":"2017-10-25","conditions":"Chronic Hepatitis b","enrollment":240},{"nctId":"NCT02976740","phase":"PHASE2","title":"SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2016-11","conditions":"Lung Cancer Metastatic","enrollment":48},{"nctId":"NCT02787447","phase":"PHASE2","title":"Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2016-05","conditions":"Lung Adenocarcinoma","enrollment":46},{"nctId":"NCT02906150","phase":"PHASE2","title":"Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type","status":"UNKNOWN","sponsor":"SciClone Pharmaceuticals","startDate":"2016-09","conditions":"Non-Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT02906163","phase":"PHASE1, PHASE2","title":"First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy","status":"UNKNOWN","sponsor":"SciClone Pharmaceuticals","startDate":"2016-10","conditions":"EGFR Mutation Positive Non Small Cell Lung Cancer","enrollment":188},{"nctId":"NCT02646189","phase":"PHASE1, PHASE2","title":"Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2011-08","conditions":"Hepatitis B, Chronic","enrollment":12},{"nctId":"NCT00935558","phase":"PHASE2","title":"Dendritic Cell Based Therapy for Breast Cancer Patients","status":"WITHDRAWN","sponsor":"Inge Marie Svane","startDate":"2009-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01031966","phase":"PHASE2","title":"A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2009-11","conditions":"END STAGE RENAL DISEASE","enrollment":120},{"nctId":"NCT00197860","phase":"PHASE1, PHASE2","title":"Dendritic Cell Based Therapy of Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2004-09","conditions":"Advanced Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT00291616","phase":"PHASE4","title":"Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2005-12","conditions":"Chronic Hepatitis B","enrollment":52},{"nctId":"NCT00711620","phase":"NA","title":"Efficacy of Thymosin alpha1 for Severe Sepsis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2008-05","conditions":"Severe Sepsis","enrollment":366},{"nctId":"NCT01178996","phase":"PHASE3","title":"Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":552},{"nctId":"NCT00911443","phase":"PHASE2","title":"Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2002-07","conditions":"Malignant Melanoma","enrollment":488},{"nctId":"NCT00001036","phase":"PHASE1","title":"The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00040027","phase":"PHASE3","title":"Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin","status":"COMPLETED","sponsor":"SciClone Pharmaceuticals","startDate":"2002-04","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":500},{"nctId":"NCT00039962","phase":"PHASE3","title":"Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin","status":"COMPLETED","sponsor":"SciClone Pharmaceuticals","startDate":"2002-05","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":500},{"nctId":"NCT00580450","phase":"PHASE1, PHASE2","title":"Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies","status":"UNKNOWN","sponsor":"University Of Perugia","startDate":"2007-12","conditions":"Hematological Malignancies","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":593,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Thymosin Alpha","genericName":"Thymosin Alpha","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Thymosin Alpha is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activation of immune cells. Used for Immunodeficiency disorders, Chronic hepatitis B, Cancer immunotherapy adjunct.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}